Cargando…

Tolerability and discontinuation rates in teriflunomide-treated patients: A real-world clinical experience

OBJECTIVES: To assess the real-world tolerability of teriflunomide in multiple sclerosis (MS) patients from a large Canadian MS Centre of Care to determine whether previously treated (PT) patients have different tolerability thresholds than treatment-naive (TN) patients, leading to differing discont...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alnajashi, Hind A., Alshamrani, Foziah J., Freedman, Mark S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Riyadh : Armed Forces Hospital 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8015587/ https://www.ncbi.nlm.nih.gov/pubmed/30007995 http://dx.doi.org/10.17712/nsj.2018.3.20180003

Ejemplares similares

Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis
por: Norborg, Hilde, et al.
Publicado: (2021)

Efficacy and Safety of Intravenous Cladribine in Patients with Rapidly Evolving or Early Secondary Progressive Multiple Sclerosis
por: Alshamrani, Foziah, et al.
Publicado: (2020)

Case Series: Myelin Oligodendrocyte Glycoprotein-Immunoglobulin G-Related Disease Spectrum
por: Alshamrani, Foziah, et al.
Publicado: (2020)

COVID-19 in teriflunomide-treated patients with multiple sclerosis
por: Maghzi, Amir Hadi, et al.
Publicado: (2020)

Characterizing lymphocyte counts and infection rates with long-term teriflunomide treatment: Pooled analysis of clinical trials
por: Comi, Giancarlo, et al.
Publicado: (2019)

Prospective Matched Case-Control Study of Over-Early P100 Wave Latency in Migraine with Aura
por: Alshamrani, Foziah J., et al.
Publicado: (2023)

Awareness of patients with multiple sclerosis in Saudi Arabia regarding the relationship between smoking and multiple sclerosis
por: Bashamakh, Lujain F., et al.
Publicado: (2019)

Clinical efficacy of teriflunomide over a fixed 2-year duration in the TOWER study
por: Freedman, Mark S, et al.
Publicado: (2018)

Real-World Observational Evaluation of Hair Thinning in Patients with Multiple Sclerosis Receiving Teriflunomide: Is It an Issue in Clinical Practice?
por: Hendin Travis, Lori, et al.
Publicado: (2018)

Teriflunomide treatment outcomes in multiple sclerosis: A Portuguese real-life experience
por: Nunes, Carla Cecília, et al.
Publicado: (2023)

Real-world outcomes of teriflunomide in relapsing–remitting multiple sclerosis: a prospective cohort study
por: Zhang, Yao, et al.
Publicado: (2022)

Neuropathy in multiple sclerosis patients treated with teriflunomide
por: Kilic, Ahmet Kasim, et al.
Publicado: (2023)

The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies
por: Freedman, Mark S, et al.
Publicado: (2017)

Effectiveness and Tolerability of Colesevelam HCl for Accelerated Elimination of Teriflunomide in Healthy Participants
por: Lunven, Catherine, et al.
Publicado: (2017)

Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry
por: Papp, Viktoria, et al.
Publicado: (2021)

Real-World Evidence for Favourable Quality-of-Life Outcomes in Hungarian Patients with Relapsing-Remitting Multiple Sclerosis Treated for Two Years with Oral Teriflunomide: Results of the Teri-REAL Study
por: Bencsik, Krisztina, et al.
Publicado: (2022)

Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis
por: Bar-Or, Amit, et al.
Publicado: (2013)

Efficacy and Safety of Teriflunomide in Multiple Sclerosis across Age Groups: Analysis from Pooled Pivotal and Real-world Studies
por: Oh, Jiwon, et al.
Publicado: (2021)

Treatment of Multiple Sclerosis With Teriflunomide. Multicenter Study of Real Clinical Practice in the Valencian Community-Spain
por: Landete, Lamberto, et al.
Publicado: (2021)

Real-world experiences: Efficacy and tolerability of pirfenidone in clinical practice
por: Fang, Chuling, et al.
Publicado: (2020)

Outcomes following mepolizumab treatment discontinuation: real-world experience from an open-label trial
por: Ortega, Hector, et al.
Publicado: (2019)

Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use
por: O’Connor, Paul W., et al.
Publicado: (2013)

Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis
por: Comi, Giancarlo, et al.
Publicado: (2020)

The effectiveness of teriflunomide in patients with multiple sclerosis in China: a real-world comparison to no DMT treatment in the first year after diagnosis
por: Bu, Bitao, et al.
Publicado: (2023)

Effectiveness and Safety of Teriflunomide in Relapsing–Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study
por: Meca-Lallana, José E., et al.
Publicado: (2023)

Real-World Assessment of Quality of Life in Patients with Relapsing Remitting Multiple Sclerosis Treated with Teriflunomide for Two Years: Patient-Reported Outcomes from the AURELIO Study in Greece
por: Dardiotis, Efthymios, et al.
Publicado: (2022)

Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS
por: Chan, Andrew, et al.
Publicado: (2020)

Teriflunomide promotes oligodendroglial differentiation and myelination
por: Göttle, Peter, et al.
Publicado: (2018)

An update of teriflunomide for treatment of multiple sclerosis
por: Oh, Jiwon, et al.
Publicado: (2013)

Teriflunomide: Lack of efficacy: case report
Publicado: (2022)

Lichenoid Drug Eruption Induced by Teriflunomide
por: Agharbi, Fatima-Zahra, et al.
Publicado: (2023)

Real-world effectiveness and safety profile of teriflunomide in the management of multiple sclerosis in the Gulf Cooperation Council countries: An expert consensus narrative review
por: Alroughani, Raed, et al.
Publicado: (2022)

Registry of patients with multiple sclerosis and COVID-19 infection in Saudi Arabia
por: Alshamrani, Foziah, et al.
Publicado: (2021)

A randomized trial of teriflunomide added to glatiramer acetate in relapsing multiple sclerosis
por: Freedman, MS, et al.
Publicado: (2015)

Predicting long-term disability outcomes in patients with MS treated with teriflunomide in TEMSO
por: Sormani, Maria Pia, et al.
Publicado: (2017)

Painful Small Fiber Neuropathy Associated With Teriflunomide: A Case Series and Literature Review Related to Teriflunomide and Leflunomide
por: Elrefaey, Ahmed, et al.
Publicado: (2023)

Oral teriflunomide in the treatment of relapsing forms of multiple sclerosis: clinical evidence and long-term experience
por: Miller, Aaron E.
Publicado: (2017)

Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study
por: Miller, Aaron E., et al.
Publicado: (2014)

Treatment Discontinuation, Adherence, and Real-World Effectiveness Among Patients Treated with Ledipasvir/Sofosbuvir in the United States
por: Puenpatom, Amy, et al.
Publicado: (2017)

Real-world treatment patterns, discontinuation and clinical outcomes in patients with B-cell lymphoproliferative diseases treated with BTK inhibitors in China
por: Yan, Yuting, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fjgt2horre7ajpuad59gbbg2iq